Rallybio (RLYB) Net Cash Flow (2020 - 2026)
Rallybio (RLYB) posted Net Cash Flow of $9.9 million for Q1 2026, up 1426.87% sequentially from -$748000.0 in Q4 2025, and up 1032.99% YoY from $876000.0 in Q1 2025.
Rallybio (RLYB) Net Cash Flow (2020 - 2026) Analysis & Trends
Rallybio has reported Net Cash Flow for 7 years, with the latest figure at $9.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 1032.99% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.5 million (up 686.47% YoY) and the FY2025 annual result came in at $17.5 million, up 264.96% from the prior year.
- Net Cash Flow climbed to $9.9 million in Q1 2026 per RLYB's latest filing, from -$748000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $22.7 million in Q3 2025 and troughed at -$93.9 million in Q1 2022.
- A 5-year average of -$7.9 million and a median of -$5.2 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2026: Net Cash Flow sank 651.81% in 2022, then jumped 1032.99% in 2026.
- Over 5 years, Net Cash Flow stood at $5.2 million in 2022, then advanced by 1.7% to $5.3 million in 2023, then sank by 313.96% to -$11.4 million in 2024, then jumped by 93.45% to -$748000.0 in 2025, then jumped by 1426.87% to $9.9 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $9.9 million, -$748000.0, and $22.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 51.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.55 Mn |
| Jun 30, 2026 | 51.55 Mn |
| Mar 31, 2026 | 9.93 Mn |
| Mar 31, 2026 | 9.93 Mn |
| Dec 31, 2025 | -748,000.00 |
| Dec 31, 2025 | -748,000.00 |
| Sep 30, 2025 | 22.68 Mn |
| Sep 30, 2025 | 22.68 Mn |
| Jun 30, 2025 | -5.33 Mn |
| Jun 30, 2025 | -5.33 Mn |
| Mar 31, 2025 | 876,000.00 |
| Mar 31, 2025 | 876,000.00 |
| Dec 31, 2024 | -11.42 Mn |
| Dec 31, 2024 | -11.42 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Mar 31, 2024 | -5.19 Mn |
| Mar 31, 2024 | -5.19 Mn |